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Background and Purpose—Common variants have been identified using genome-wide association studies which contribute 
to intracranial aneurysms (IA) susceptibility. However, it is clear that the variants identified to date do not account for the 
estimated genetic contribution to disease risk.
Methods—Initial analysis was performed in a discovery sample of 2617 IA cases and 2548 controls of white ancestry. Novel 
chromosomal regions meeting genome-wide significance were further tested for association in 2 independent replication 
samples: Dutch (717 cases; 3004 controls) and Finnish (799 cases; 2317 controls). A meta-analysis was performed to 
combine the results from the 3 studies for key chromosomal regions of interest.
Results—Genome-wide evidence of association was detected in the discovery sample on chromosome 9 (CDKN2BAS; 
rs10733376: P<1.0×10−11), in a gene previously associated with IA. A novel region on chromosome 7, near HDAC9, 
was associated with IA (rs10230207; P=4.14×10−8). This association replicated in the Dutch sample (P=0.01) but failed 
to show association in the Finnish sample (P=0.25). Meta-analysis results of the 3 cohorts reached statistical significant 
(P=9.91×10−10).
Conclusions—We detected a novel region associated with IA susceptibility that was replicated in an independent Dutch 
sample. This region on chromosome 7 has been previously associated with ischemic stroke and the large vessel stroke 
occlusive subtype (including HDAC9), suggesting a possible genetic link between this stroke subtype and IA.   (Stroke. 
2014;45:3194-3199.)
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Subarachnoid hemorrhage (SAH) because of the rupture of an intracranial aneurysm (IA) occurs in 16 000 to 17 000 
persons in the United States annually, over 40% die within 
30 days.1,2 There is evidence that aneurysmal SAH has a 
genetic contribution. First degree relatives of an SAH patient 
have 2× to 6× greater frequency of an SAH compared with 
age-matched controls.3–6 First and second degree relatives of 
a patient with SAH or IA also have a greater risk of an unrup-
tured IA (8.7%–13.9%), compared with the general popula-
tion (1%).7–9 These data support a genetic contribution but 
could also be because of common lifestyle-related risk factors.
Genome-wide association studies identified and replicated 
significant associations at chromosome 4q31.23 (EDNRA), 
5q31.3, 6q24.2, 8q12.1 (SOX17), 9p21.3 (CDKN2A/
CDKN2B/CDKN2BAS), 10q24.32 (CNNM2), 12q22, 13q13.1 
(KL/STARD13), 18q11.2 (RBBP8), and 20p12.1.10–15 We used 
a case–control design to identify additional loci associated 
with IA in a large sample of European ancestry. IA cases 
were enriched for a positive family history of IA, which may 
increase the contribution of genetic factors. Two independent 
replication samples were examined to confirm the most prom-
ising findings in the discovery sample.
Subjects and Methods
Discovery Sample
The discovery sample involved 2617 white IA cases and 2548 white 
controls identified through different studies. Some of these samples 
were reported as part of a previous analysis.12 IA cases were ascer-
tained through 5 studies and controls through 5 studies. All studies 
obtained appropriate institutional ethics approvals (Materials in the 
online-only Data Supplement).
Genotyping and Quality Review
The discovery sample, with the exception of the Atherosclerosis Risk 
in Communities (ARIC) samples, was genotyped on the Affymetric 
Axiom array. The ARIC samples were genotyped on the Affymetric 
single nucleotide polymorphism (SNP) array 6.0. All released Axiom 
genotypes underwent a common quality review pipeline that included 
identification of sample duplicates, related individuals, and sex dis-
crepancies. Before performing imputation, SNPs were excluded if 
there were (1) improper mapping to Genome Reference Consortium 
GRCh37, (2) a minor allele frequency <0.03, (3) SNP genotype call 
rate <95%, or (4) Hardy–Weinberg Equilibrium P<10−4 in controls. 
Minor allele frequency and call rates were calculated by combining 
all Axiom array data. From the 597 320 SNPs on the Axiom array, 
464 632 were retained after this quality review. The ARIC samples 
genotyped on the Affymetric SNP array 6.0 underwent the same qual-
ity review as the Axiom genotypes. From the 793 799 autosome SNPs 
on the Affymetric SNP array 6.0 that were provided by ARIC after 
their initial data review, a total of 626 645 were retained (Materials in 
the online-only Data Supplement).
Principal component analysis was performed using the SNPs gen-
otyped on both the Axiom and Affymetric SNP array 6.0 platforms. 
Analyses were performed using Eigenstrat16 using data from 11 
HapMap phase III populations. To ensure that the discovery sample in-
cluded only white subjects, all samples clustering outside the Utah resi-
dents of northern and western European ancestry and Toscans in Italy 
samples were excluded from further analysis. (Materials in the online-
only Data Supplement; Figure I in the online-only Data Supplement).
Imputation and Statistical Analysis
Imputation was performed for all autosomes using IMPUTE2 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). All samples 
genotyped on the Axiom array that passed quality review (n=4060) 
were imputed together using the 1000Genomes haplotypes (n=1092) 
as the phased reference panel. Only variants with >1 minor copy 
across all 1000Genome populations were imputed. Original geno-
types were not overwritten. ARIC samples that passed quality review 
(n=1132) were imputed separately using the same reference panel.
All ARIC samples genotyped on the Affymetrix SNP array 6.0 
were controls, whereas all cases and the remaining controls were gen-
otyped on the Axiom array. Therefore, extensive and detailed quality 
review was performed to ensure that spurious association was not de-
tected based on platform effects. SNPs imputed in all data sets were 
not included in the analysis sample; only SNPs genotyped on at least 
one of the arrays (1 195 878 SNPs) were considered for inclusion in 
the analysis. We used the approach described by Sinnott and Kraft17 
which implements an aggressive filtering approach to remove SNPs 
having the potential for systematic platform differences (Materials in 
the online-only Data Supplement). The final data set retained 672 210 
autosome SNPs for analysis.
The genotyped and imputed SNPs were tested for association with 
IA susceptibility using a logistic regression model. No additional co-
variates such as principal components for ancestry were necessary. 
Analysis was performed using the SNPTEST v2 software using an 
additive model of SNP effect. Imputed genotypes were encoded in the 
logistic model as the expected allele count.18 For autosomal SNPs, all 
samples were analyzed together. For chromosome X, only SNPs that 
were on the Axiom array were included because the ARIC study sam-
ples only had genotypes for autosomal SNPs. Using the same quality 
control as above, 13 071 chromosome X SNPs were used. Genomic 
control was applied to correct for inflation (initial lambda λ =1.104; 
after genomic control, λ =1.0). Between the autosomes and X chro-
mosome SNPs, the data set included 685 281 SNPs for the association 
analysis. We applied a Bonferroni correction to obtain the appropriate 
genome-wide threshold for significance (0.05/685 281=P<7.3×10−8).
To test whether there might be more than one risk variant in a 
particular gene or gene region contributing to the association, condi-
tional analyses were performed. A logistic regression model was used 
to include the genotype at the most significant SNP from the meta-
analysis and to test for association with other SNPs in the region.
Replication and Meta-Analysis
Two independent case–control cohorts were used as replication 
samples. The first was a Dutch case–control sample. Patients with 
IA (n=786) admitted to the Utrecht University Medical Center (in 
The Netherlands) between 1997 and 2007 were included. This includ-
ed both patients with ruptured and unruptured IA (Materials in the 
online-only Data Supplement). Controls were 3110 Dutch subjects 
recruited as part of the Nijmegen Biomedical Study and the Nijmegen 
Bladder Cancer Study.19,20
The second replication cohort was a case–control Finnish sample. 
The patients with IA (n=851), included both ruptured and unrup-
tured IA, treated at the Helsinki and Kuopio University Hospitals 
(Materials in the online-only Data Supplement). Controls were 2317 
Table 1. Sample Demographics for Study Cases 
Cases Number
Mean Age of 
Onset (SD) % Male
FIA Study multiplex families (1/family) 388 50.7 (11.9) 31.4
FIA Study (general recruitment) 1441 54.1 (11.7) 20.1
GERFHS 44 54.7 (12.9) 40.9
Australia 118 53.4 (16.3) 34.8
UCSF 128 55.8 (12.0) 32.8
Poland 498 52.1 (12.9) 41.2
Total number of cases 2617 53.2 (12.3) 27.4
FIA indicates Familial Intracranial Aneurysm; GERFHS, Genetic and 
Environmental Risk Factors for Hemorrhage Stroke; and UCSF, University of 
California, San Francisco.
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Finnish individuals from 3 samples (Materials in the online-only Data 
Supplement): (1) Anonymous Finnish patients at the same hospitals 
as Finnish cases who gave blood samples for unrelated causes in con-
secutive days, (2) the Helsinki Birth Cohort Study (HBCS),21 and (3) 
The Health 2000 cohort.22,23
The replication cohorts were genotyped on the Illumina CNV370-
duo chips (Illumina Inc., San Diego, CA), and results were previously 
reported.10,15 Extensive quality control was performed in both sub-
ject and SNP data. Imputation was also performed in these samples 
(Materials in the online-only Data Supplement). The final Replication 
Samples included 717 Dutch cases, 3004 Dutch controls, 799 Finnish 
cases, and 2317 Finnish controls.
Replication was performed initially by reviewing results in each 
of the replication studies for the SNP on chromosome 7 that was 
found to be significantly associated with IA in the discovery sam-
ple. Replication was defined as P≤0.01 in either of the replication 
samples, with the direction of the SNP effect the same as in the 
Discovery Sample.
Subsequently, meta-analysis was performed in the chromosome 7 
region by combining individual SNP results from the discovery sam-
ple and the replication sample. METAL24 was used using an inverse-
variance weighting scheme. We evaluated results to identify findings 
meeting genome-wide significance criteria.
Results
Discovery Sample
The final sample included 2617 IA cases and 2548 controls 
(Tables 1 and 2). The cases across the studies had similar 
age of onset and all had a preponderance of females. The 
controls across the studies also had a similar age at the time 
of recruitment.
The most significant genome-wide results included 
SNPs in CDKN2BAS, also known as ANRIL (rs10733376; 
P=4.07×10−12; odds ratio=1.34; 95% confidence interval: 
1.23–1.45) on chromosome 9 (Figures 1 and 2A) previously 
associated with IA, as well as with other phenotypes.12–15 An 
SNP on chromosome 7 also met genome-wide significance 
(rs10230207; P=4.14×10−8; Figures 1 and 2B). This SNP is in 
an intergenic region 3′ of TWISTNB, MIR3146, and TMEM196 
and near SNPs previously associated with ischemic stroke and 
large vessel occlusive ischemic subtype.25 On chromosome 5, 
rs9687972 also reached genome-wide significance; however, 
no other SNPs in the same region provided similar evidence 
of association. This SNP was genotyped in the Axiom samples 
and imputed in the ARIC samples. The imputation informa-
tion metric is 0.966, which indicates a good imputation; how-
ever, the genotype call rate in the Axiom samples was 95.5%, 
just above our threshold of 95%. The minor allele frequencies 
are 0.130 (in ARIC controls) and 0.115 (in Axiom controls; P 
value is 0.12, just above our threshold of 0.1). Therefore, this 
finding is likely a false-positive association.
On chromosome 7, imputed SNPs were analyzed to eval-
uate further the evidence of association. As expected, the 
imputed SNPs in high linkage disequilibrium (LD) with the 
most significant SNPs initially analyzed further supported the 
association with IA. The 3 neighboring regions on chromo-
some 7 which were examined (Figure 2C) were independent 
of each other, suggesting that there might be independent evi-
dence of association to IA susceptibility factors within this 
chromosomal region. Conditional analysis was performed and 
as expected, based on the lack of LD between the primary 
region and the 2 more distant regions, conditioning on the most 
significant SNP (rs10230207) did not significantly reduce the 
evidence of association in the other regions. However, none of 
these other regions on chromosome 7 attained genome-wide 
criteria, and therefore these results remained tentative.
Results did not exceed the genome-wide threshold in any 
other chromosomal region. In the chromosomal regions nomi-
nated by previous studies, P<0.01 was attained with the key 
SNPs nominated at chromosomes 4q31.23 and 8q12.1. In 
addition, although top SNPs previously reported on chromo-
somes 13q13.1 and 18q11.2 were not available in our sample, 
SNPs in LD with these SNPs attained P<0.01 (Figure II in the 
online-only Data Supplement).
Replication Sample
Two independent replication samples were analyzed for evi-
dence of association the SNPs on chromosome 7 identified 
in the discovery sample. The sample demographics are in 
Tables 3 and 4.
Initially, only the single SNP (rs10230207) which had 
attained genome-wide evidence of association in the discovery 
sample was tested for association. When analyzing this SNP, 
the Dutch sample provided replication (P=0.01), whereas the 
Table 2. Sample Demographics for Study Controls
Controls Number
Mean Age at  
Recruitment (SD) % Male
CCC 294 64.0 (14.8) 46.9
GERFHS 484 66.3 (13.0) 52.7
Australia 154 50.9 (16.1) 39.0
Poland 484 56.2 (15.8) 39.7
ARIC 1132 54.3 (7.5) 27.9
Total number of controls 2548 57.9 (13.1) 37.7
ARIC indicates Atherosclerosis Risk in Communities; CCC, Cincinnati Control 
Cohort; and  GERFHS, Genetic and Environmental Risk Factors for Hemorrhage 
Stroke.
Figure 1. Genome-wide association analysis in the discovery 
sample. X axis is the physical position along the genome. Y axis 
denotes the –log10(P value) for association.
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Finnish sample failed to do so (P=0.25). Subsequently, meta-
analysis was performed across the discovery sample and the 2 
replication samples (Table 5).
Discussion
We detected genome-wide evidence of association to a novel 
region on chromosome 7. The evidence of association was 
replicated in an independent Dutch sample with the same SNP 
(rs10230207) and in the same direction of effect. This region 
failed to show replication in the Finnish cohort, although the 
direction of effect was the same as in the other 2 samples 
and may be because of the different genetic architecture of 
the Finnish population. In addition, the incidence of SAH 
is higher in Finland compared with most other parts of the 
world,26 suggesting that unique genetic factors may segregate 
in the Finnish population. Another possible explanation is 
that the size of the replication samples did not have sufficient 
power to replicate the association. Of note, the association on 
chromosome 9 with ANRIL has been replicated across many 
European populations, including the Finns.13
The region on chromosome 7 identified in this study was 
associated with other stroke phenotypes in previous genome-
wide association studies. Matarín et al25 reported association 
to chromosome 7p21.1 for ischemic stroke, although the find-
ing did not meet genome-wide significance. Support for the 
association of ischemic stroke to this region was also found 
in a Han Chinese sample.27 Large vessel stroke was associ-
ated with SNPs in HDAC9 on chromosome 7p21.128 ≈600 kb 
away from the initial reports for the more general ischemic 
stroke phenotype. Two other genes, TWIST1 and FERD3L, 
downstream of HDAC9 could not be excluded as underlying 
the association. Interestingly, unlike the earlier reports from 
Matarin and Ding, the SNPs in this region were not associated 
Figure 2. Regional association results in the discovery sample. X axis is the physical position on the chromosome (Mb). Y axis denotes 
the –log10(P value) for association. The most significantly associated SNP is shown with purple diamond. The extent of linkage disequilib-
rium (LD; r2) between each SNP and the most significantly associated SNP is indicated by the color scale at top right. Larger values of r2 
indicate greater LD. A, chromosome 9; B, chromosome 7; and C, chromosome 7 (expanded view).
Table 3. Replication Sample Demographics for Study Cases 
Cases Number Mean Age of Onset % Male
Dutch 717 54.4 31.2
Finnish 799 49.6 42.2
Table 4. Replication Sample Demographics for Study 
Controls
Controls Number Mean Age at Recruitment % Male
Dutch 3004 61.7 62.8
Finnish 2317 60.9 53.7
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with the general ischemic stroke phenotype or other sub-
types, such as small vessel stroke or cardioembolic stroke. 
The METASTROKE Collaboration confirmed the association 
of large vessel stroke the region around HDAC9.29
Our genome-wide significant association is closest to the find-
ing by Matarin. There is LD between our top SNP (rs10230207) 
and theirs (r2=0.921). In our study, SNPs in and around HDAC9 
did not attain genome-wide significance, but they provided 
modest evidence of association (P=10–6; Table 5) that was inde-
pendent of the association with rs10230207. The Dutch and 
Finnish sample did not have significant evidence of linkage with 
the SNPs in and around HDAC9. We also did not find exten-
sive LD (r2=0.117) between our top SNP in this region and the 
SNP reported by the International Stroke Genetics Consortium 
(rs11984041). We performed a similar comparison with the 
METASTROKE association. We had modest evidence of asso-
ciation with the SNPs in the METASTROKE-associated region 
(P<10–5); however, our most significant SNP was not in LD with 
the SNP identified in the METASTROKE study (rs2107595).
Our results along with those of other stroke consortium 
suggest that this region on chromosome 7 is associated with 
both IA and large vessel ischemic stroke subtype. Combined 
with our observation, one could speculate that IA, a disease 
of large intracranial arteries, and ischemic stroke because of 
large artery disease may share similar gene pathways and 
overlapping pathophysiology. Interestingly, the strongest 
genome-wide association studies evidence for IA to this point 
is for the region on chromosome 9p21.3, which has also been 
linked to large vessel ischemic stroke, myocardial infarction, 
and aortic aneurysm. Thus, genetic risk factors for large vessel 
vasculopathy may lead to different phenotypes depending on 
coexisting risk factors such as smoking, hypertension, hyper-
lipidemia, and other genetic risk factors.
A recent meta-analysis combined results from 61 candi-
date gene and genome-wide association studies and used 
association analysis to identify genes contributing to IA sus-
ceptibility.30 The overall number of samples was 32 887 IA 
cases and 83 683 controls. The strongest evidence of asso-
ciation was on chromosome 9 in CDKN2B, chromosome 8 
near SOX17, and chromosome 4 near EDNRA. These results 
were influenced by the available data, which typically did 
not include results for all SNPs, making it difficult to detect 
association to SNPs that were not identified in the initial 
report. In addition, by including candidate gene papers, the 
amount of available data was also limited, reducing the abil-
ity to detect novel associations in regions that have not yet 
been studied in the context of IA.
In summary, we identified and replicated in one sample a 
novel association with IA on chromosome 7 in a region pre-
viously reported to be associated with stroke. The associated 
region is near, although not in LD with HDAC9, which has 
been associated with large vessel stroke. Studies to replicate 
this association in additional cohorts of European or other 
ancestry are necessary and may suggest some overlapping 
pathogenesis across stroke types and would provide important 
new insights into the causes and potential targets for stroke 
prevention.
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rs7798197 and rs12669789 are top SNPs in second and third region, respectively. 95% CI indicates 95% confidence interval for the odds ratio; and OR, odds ratio.
*rs10230207 achieved genome-wide significance in the discovery sample and the SNP tested initially for replication.
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SUPPLEMENTAL MATERIAL 
 
Discovery Sample 
Familial Intracranial Aneurysm Study (FIA Study): Families with at least 2 members who 
had intracranial aneurysm(s) (IA) were ascertained through 26 clinical centers (41 sites) in North 
America, New Zealand, and Australia. Exclusion criteria included (i) a fusiform-shaped 
unruptured IA of a major intracranial trunk artery; (ii) an IA that is part of an arteriovenous 
malformation; (iii) a family or personal history of polycystic kidney disease, Ehlers Danlos 
syndrome, Marfan’s syndrome, fibromuscular dysplasia, or Moya-Moya disease; or (iv) failure 
to obtain informed consent from the patient or family members. All medical records and relevant 
accompanying data were reviewed by a Verification Committee. The FIA study was approved by 
the Institutional Review Boards/Ethics Committees at all clinical and analytical centers and 
recruitment sites. 
 
For the present analysis, only individuals having an IA based on an intra-arterial angiogram, 
operative report, autopsy, or size ≥7 mm on non-invasive imaging (MRA, CTA) were considered 
“definite” cases. A set of independent unrelated cases obtained by selecting one individual with 
definite IA from each FIA family self-reported as Caucasian (n=388) was included in Discovery 
Sample 1.  Samples from an additional 30 Caucasian cases were included in Discovery Sample 
3, and 1 case was included in Discovery Sample 4. Results from Discovery Sample 1 were 
previously published.
1
  
 
Further recruitment was undertaken as part of the FIA Study and the requirement for family 
history of IA was removed and both familial and sporadic IA cases were enrolled. The same 
exclusion criteria were in place and all cases underwent the same rigorous review from the 
Verification Committee. A set of 829 Caucasian IA cases was selected for genotyping in 
Discovery Sample 2.  An additional 607 Caucasian IA cases were included in Discovery Sample 
3, and 42 were included in Discovery Sample 4 
 
Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS): 
Caucasian cases and controls identified from other studies, including those from the Australasian 
Cooperative Research on Subarachnoid hemorrhage Study (ACROSS), which was a prospective, 
population-based, case-control study of SAH undertaken in three cities in Australia and one city 
in New Zealand during the mid-1990s.
2
 ACROSS included incidence cases of SAH secondary to 
documented or presumed ruptured IA who were frequency-matched (by sex, 10-year age strata, 
and city of residence) to controls selected from electoral rolls in each city. Detailed information 
about key exposures, such as smoking, hypertension, family history of stroke/IA, was obtained 
by standardized interviews with subjects (or proxies) and where possible, blood samples were 
obtained for storage and future DNA extraction. Samples from a total of 135 cases and 168 
controls were available for genotyping in Discovery Sample 2. This study was approved by the 
institutional review committees at 10 sites. This sample has been has been included in a previous 
report.
1
 
 
UCSF: The University of California, San Francisco recruited a prospective cohort of adult 
patients with spontaneous SAH due to IA who were admitted to a tertiary-care referral center in 
San Francisco during 2003 to 2008. Cases were confirmed by non-contrast CT and cerebral 
angiogram.  After excluding subjects based on FIA exclusion criteria, 184 samples from 
Caucasian subjects with detailed medical histories and blood banked for DNA were available for 
genotyping in Discovery Sample 2. This study was approved by the institutional review 
committee at University of California, San Francisco. This sample has been has been included in 
a previous report.
1
 
 
ARIC:  Genotypic data from a set of 1148 white controls, included in Discovery Sample 2, were 
obtained through a collaborative agreement with the Atherosclerosis Risk in Communities 
(ARIC) study. In the ARIC sample, a subset of subjects who never had a stroke or TIA was 
matched to the cases in Discovery Sample 2 cases by sex and, where possible, by age (±5 years).  
However, because the age of the ARIC controls was limited to 44–66, cases younger than 39 or 
older than 71 at onset were matched to controls outside of the 5-year criterion. Genotyping had 
been performed previously using the Affymetrix SNP array 6.0.
3
 This sample has been has been 
included in a previous report.
1
 
 
Cincinnati Control Cohort and Genetic and Environmental Risk Factors for Hemorrhage 
Stroke: Controls were obtained from two population-based studies. The first was the NINDS-
funded case-control Genetic and Environmental Risk Factors for Hemorrhage Stroke (GERFHS) 
study, which was designed to identify the important environmental and genetic risk factors for 
IA-related SAH as well as for spontaneous intracerebral hemorrhage. Controls identified by 
random-digit telephone dialing from the Greater Cincinnati/Northern Kentucky community and 
matched to enrolled cases by age (±5 years), gender, and race, had the same interview questions 
regarding environmental risk factors as FIA study participants. Another set of controls free of 
stroke and IA were selected from the Cincinnati Control Cohort (CCC). The subjects in this 
cohort were identified by random-digit dialing from the Greater Cincinnati region during 2006.  
These subjects had blood drawn for DNA extraction as well as extensive interviews including 
detailed environmental exposures as well as detailed medical history of every major disease. 
Both studies were approved by the Institutional Review Boards of the University of Cincinnati 
and all participating hospitals. 113 GERFHS and 290 CCC controls have been included in a 
previous report.
1
 375 GERFHS and 7 CCC controls were not previously analyzed. 
 
Krakow, Poland: IA cases were recruited from patients of the Department of Neurology and the 
Department of Neurosurgery and Neurotraumatology of the Jagiellonian University in Krakow. 
Both subjects with ruptured IAs and with unruptured IA were recruited. Presence of IA was 
confirmed by intra-arterial angiogram, CTA, MRA or intraoperatively. A total of 504 IA patients 
were included. The control group included 514 unrelated subjects taken from the population of 
southern Poland. Control subjects had no apparent neurological disease based on the findings in 
a structured questionnaire and a neurological examination. All subjects were of European 
descent. Information about key demographics, family history and risk factors were obtained 
using a standardized questionnaire. The study was approved by the institutional review board of 
the Jagiellonian University. All Polish samples were included in Discovery Sample 4. 
 
Genotyping and Quality Review 
 
Genotyping of all samples except ARIC was performed using the Axiom array at the Affymetrix 
core labs. Genotyping was performed in four batches using similar methods and quality control. 
Forty-eight internal samples were genotyped twice for quality control. This yielded a total of 
4,323 samples sent for genotyping. However, only 4,249 samples with a QC (dQC) value ≥0.82 
and an initial call rate of 97% were released. All released genotypes underwent a common 
quality review pipeline which included identification of sample duplicates, related individuals, 
and gender discrepancies, which resulted in the removal of 118 samples. Prior to performing 
imputation, SNPs were excluded if there were: (i) improper mapping to Genome Reference 
Consortium GRCh37; (ii) a minor allele frequency (MAF) <0.03; (ii) a SNP call <95%; (iv) a 
Hardy Weinberg Equilibrium (HWE) p-value <10
-4
 in control samples. MAF and call rates 
were calculated by combing all 4 batches together. From the 597,320 SNPs on the Axiom array, 
464,632 were retained following this quality review.  
 
Genotypic data for the ARIC samples was obtained from the Affymetric SNP array 6.0.
3
 These 
data also underwent quality review and SNPs were removed based on the same criteria listed 
above. From the 793,799 autosome SNPs on the Affymetric SNP array 6.0 that were provided 
by ARIC following their initial data review, a total of 626,645 were retained for imputation in 
this study. 
 
A principal component analysis (PCA) was performed using Eigenstrat
4
 and data from 11 
HapMap phase III populations to identify clusters using the first two eigenvectors computed 
using the SNPs typed on both platforms. Samples clustering with the European American (CEU 
and TSI) reference set were retained, and those outside this cluster which were likely to contain 
African, Asian, or Hispanic admixture were removed from further analysis (n=61 of the Axiom-
genotyped samples); 16 non-European American samples from the ARIC set were also removed 
(Supplemental Figure 1). 
 
Imputation  
 
Imputation was performed for all autosomes using IMPUTE2 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). We have employed the 
recommendation of Howie et al
5
 to include diverse reference panels to optimize imputation. 
All distinct samples genotyped on the Axiom array (n=4060) were imputed together using the 
1000Genomes haplotypes (n=1092; data freeze from Nov. 2010, May. 2011, March 2012 phased 
haplotype release) as the phased reference panel. Only variants with more than one minor copy 
across all 1000Genome populations were imputed. Original genotypes were not overwritten. 
ARIC sample (n=1132) were imputed separately using the same reference panel. Only SNPs 
genotyped on at least one of the arrays (1,195,878 SNPs) were used in the analysis.   
 
Statistical Analysis 
 
The discovery sample consists of samples recruited through multiple studies, some 
providing both cases and controls and others providing only cases or controls. As a result, 
we could not analyze each study separately and combine results using meta-analysis. 
Rather, we have combined all data available from our discovery sample and performed 
detailed quality review to reduce sources of false positive results due to population 
stratification and inter-study differences.  
 
Because our sample was genotyped on two platforms, with all samples genotyped in Affymetric 
SNP array 6.0 being controls, extensive and detailed quality review was performed to ensure 
that spurious association was not detected based on platform effects. As suggested by Sinnott 
and Kraft
6
 we reviewed several SNP metrics, including imputation quality (information) and 
differences in SNP minor allele frequency in controls genotyped on the Axiom platform, and the 
ARIC controls genotyped on the Affymetric SNP array 6.0. We removed all SNPs with low 
imputation quality (information score <0.30) as well as SNPs with a significant difference in 
minor allele frequency between the two sources of control samples (p<0.1). To further reduce the 
influence of rare SNPs, which would typically have less accurate imputation, we removed all 
SNPs with a minor allele frequency less than 5%. Using this aggressive filtering approach, we 
retained 672,210 SNPs for analysis. Remaining uncertainty in the imputed genotypes after 
application of the aggressive information score and minor allele frequency filters was modeled 
using the “-method score” option in SNPTEST V2. We would expect a slight loss of power in 
the association tests due to the uncertainty in genotypes; however, previous studies indicate this 
power loss is minimal, on the order of 7% of the effective sample size on average.
7
 All samples 
were analyzed together with genomic control applied to correct for inflation.  
 
Replication Sample 
 
Two independent samples were used to replicate the primary findings from this study.  
 
Dutch sample: IA patients (n=786) were admitted to the Utrecht University Medical Center (the 
Netherlands) between 1997 and 2007. The population consisted of 247 men and 539 women and 
included both patients with ruptured (727) and patients with only unruptured (59) IA. Ruptured 
IA were defined by symptoms suggestive of subarachnoid hemorrhage (SAH) combined with 
subarachnoid blood on a computed tomography (CT) scan and a proven aneurysm at 
angiography (conventional angiogram, CT- or magnetic resonance (MR)-angiogram). 
Unruptured IA were identified by CT or MR angiography or conventional angiography in the 
absence of clinical or radiological signs of SAH.
8-11
 Patients with fusiform IA, possible traumatic 
SAH, and polycystic kidney disease were excluded.  As controls, we included 3110 Dutch 
subjects, who were recruited as part of the Nijmegen Biomedical Study (n=1832) and the 
Nijmegen Bladder Cancer Study (n=1278).
12, 13
  
 
Finnish sample: The Finnish cohort consisted of 880 IA patients treated at the Helsinki and 
Kuopio University Hospitals, and included both patients with ruptured and unruptured IA.
11
 The 
patients were collected from the registries of Neurosurgery, Kuopio University Hospital, and 
Neurosurgery, Helsinki University Hospital, solely serving their catchment populations in 
Eastern and Southern Finland, respectively. The sporadic IAs (sIAs) were angiographically 
verified and the cases of subarachnoid hemorrhage from ruptured with computed tomography 
(CT).  Patients with fusiform IA (n=5), (not verifiable) traumatic SAH (n=81), and polycystic 
kidney disease (n=4) were removed.  Controls were genetically matched to cases from thee 
sample sets: anonymous donors from Kuopio University Hospital and Helsinki, the Helsionki 
Birth Cohort Study (HBCS) and the Health 2000 study (H2000).  Anonymous donors were 
individuals who were Finnish patients at the same hospitals as Finnish cases and gave blood 
samples for unrelated causes in consecutive days.
11
 The Helsinki Birth Cohort Study (HBCS) 
includes 8,760 individuals born in the Helsinki Central Hospital between 1934 and 1944.
14
 A 
subset of 1676 Illumina genotyped individuals were available for the present study. The Health 
2000 Cohort (H2000) includes 2,402 Finns, and of those 2,138 Illumina genotyped individuals 
were available for the present study
15, 16
 
 
Replication sample genotyping and quality review 
 
First, a sliding window approach was used to thin the set of SNPs to be approximately 
independent of each other. A sliding window of 1500 SNPs was shifted by 150 SNPs at a time 
along chromosomes, and in each step SNPs were filtered if any pairwise r2 was > 0.2, resulting 
in 79596 independent SNPs. Pairwise IBS distances of these SNPs were used in 
multidimensional scaling and four first dimensions were used in matching. Plink v. 1.07
17
 was 
used for thinning and MDS analysis. R package optmatch was used to pair each case to three 
controls. After 1:3 matching, additionally all Eastern Finnish controls from the previous sIA 
study were included.
17
 
 
All case and control subjects from the Dutch samples were genotyped on the Illumina CNV370 
Duo BeadChips in previous GWAS.
8, 11
 Some of the Finnish samples had also been previously 
genotyped. PLINK version 1.07 was used for quality control of both subjects and SNPs. After 
removal of SNPs with A/T or C/G alleles and SNPs that were not called in any individual, we 
performed sample QC and SNP QC. 
 
We performed sample QC after merging cases and controls, using a subset of common, high-
quality SNPs (as defined by SNPs without deviation from Hardy-Weinberg equilibrium (HWE) 
(p > 0.001), with high minor allele frequency (> 20%) and with low missingness (<1%)), and 
performed pruning based on linkage disequilibrium (r
2 
> 0.5). Subjects were removed based on 
the following three criteria: genotype missingness (subjects with a call rate below 95% were 
removed), heterozygosity (subjects were excluded if the inbreeding coefficient deviated more 
than 3 standard deviations from the mean) and cryptic relatedness (by calculating identity-by-
descent (IBD) for each pair of individuals). In each pair with an IBD proportion of at least 20%, 
a subject was excluded, if it exhibited distant relatedness with multiple individuals. For case-
control pairs, we removed the control subject. In the remaining pairs, the subject with the lowest 
call rate was excluded.  
 
We performed principal component analysis (PCA) using EIGENSTRAT on the study subjects 
and HapMap-CEU subjects. We excluded SNPs from three regions with known long-distance 
linkage disequilibrium (LD): the major histocompatibility (MHC) region (chr6: 25.8-36 Mbp), 
the chromosome 8 inversion (chr8: 6-16 Mbp) and a chromosome 17 region (chr17: 40-45 Mbp). 
We created multi-dimensional scaling plots with the first 4 principal components (PCs), using R 
version 2.11.
13, 18
 
 
Based on visual inspection of these plots, we excluded subjects that appeared 
to be outliers with respect to the CEU or the study population. After outlier removal, we 
recomputed principal components to include as covariates for logistic regression. 
 
After sample QC, we excluded SNPs with more than 2% missing genotypes, a minor allele 
frequency < 1%, genotype missingness higher than the minor allele frequency and HWE 
deviation (p < 0.001). We performed these QC steps in each study cohort separately and again 
after merging cases and controls. We also removed SNPs with a differential degree of 
missingness between cases and controls (p < 1x10
-5
; chi-squared test).   
 
The final sample included 717 Dutch cases, 3004 Dutch controls, 799 Finnish cases, 2317 
Finnish controls.  
 
Imputation, association analysis 
 
Genotype imputation was performed using the prephasing/imputation stepwise approach 
implemented in IMPUTE2 and SHAPEIT (chunk size of 3 Mb and default parameters).
5, 19
 The 
imputation reference set consisted of 2,184 phased haplotypes from the full 1000 Genomes 
Project data set (February 2012; 40,318,253 variants). All genomic locations are given in NCBI 
Build 37/UCSC hg19 coordinates. Association testing was carried out in PLINK using imputed 
SNP dosages and the principal components described above as covariates.  
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Supplemental Figure I: Principal component clustering plot for genotyped study subjects. 
Genotyped individuals are shown for PC1 (x-axis) and PC2 (y-axis). Reference populations are: 
CEU_TSI (Utah residents with Northern and Western European ancestry from the CEPH collection; 
Tuscans in Italy); CHB_CHD_JPT (Han Chinese in Beijing, China; Chinese in Metropolitan Denver, 
Colorado; Japanese in Tokyo, Japan); YRI (Yoruba in Ibadan, Nigeria).  Study samples clustering 
outside the area defined by the CEU and TSI reference samples were excluded from association 
analyses. 
 
 
Supplemental Figure II: Comparison with previously reported results from genomewide 
association studies. (A) Chromosome 4q31.23; (B) Chromosome 5q31.3; (C) Chromosome 
6q24.2; (D) Chromosome 8q12.1; (E) Chromosome 10q24.32; (F) Chromosome 12q22; (G) 
Chromosome 13q13.1; (H) Chromosome 18q11.2; (I) Chromosome 20p12.1. X-axis is the 
physical position on the chromosome (Mb). Y-axis denotes the –log10(p-value) for association. 
The most significant SNP from the initial report is shown at the top of each panel. The extent of 
LD (as measured by r
2
) between each SNP and the most significant SNP from the initial report is 
indicated by the color scale at top right. Larger values of r
2
 indicate greater LD.  If the SNP was 
available in our sample as either a genotyped or imputed SNP, the associated p-value is shown as 
a purple diamond. If the SNP was not available in our sample, the position of the SNP is shown a 
white diamond along the X axis. 
 
 
 
Supplemental Figure II-A:  Chromosome 4q31.23 
 
 
 
 
Supplemental Figure II-B:  Chromosome 5q31.3 
 
 
 
 
Supplemental Figure II-C:  Chromosome 6q24.2 
 
 
 
Supplemental Figure II-D:  Chromosome 8q12.1 
 
 
 
Supplemental Figure II-E:  Chromosome 10q24.32 
 
 
 
Supplemental Figure II-F: Chromosome 12q22 
 
 
Supplemental Figure II-G: Chromosome 13q13.1 
 
 
Supplemental Figure II-H: Chromosome 18q11.2 
 
 
Supplemental Figure II-I: Chromosome 20p12.1  
 
